No abstract

Purpose of Review This review describes the clinical presentation and treatment for cannabinoid hyperemesis syndrome (CHS). Typical treatment for nausea, vomiting, and abdominal pain may not be effective in patients with CHS. Alternative treatments have been suggested. Recent Findings The pathophysiology of CHS may be due to dysregulation of the endocannabinoid system. Two cannabinoid receptors (CB1, CB2) have been identified. Theories proposed to explain CHS including chronic stimulation of the CB1 receptor, binding of the CB1 receptor causing decreased gut motility, desensitization of CB1 receptors (these CB1 receptors generally have antiemetic effects), or interaction of the TRVP-1 receptor with the ennocannabinoid system. Summary CHS should be in the differential diagnosis for any patient with nausea, vomiting, and abdominal pain. The usual treatment for nausea, vomiting, and abdominal pain may not be effective for patients with CHS. Other newer, off-label treatments for CHS have been proposed. Keywords Cannabinoid hyperemesissyndrome. CHS. Chronicabdominal pain. Chronic marijuanauseand vomiting,hot shower for vomiting control, capsaicin for CHS, haloperidol for CHS This article is part of the Topical Collection on Pain Management

No abstract

No abstract